BioCentury
ARTICLE | Clinical News

Arcturus Therapeutics preclinical data

February 3, 2014 8:00 AM UTC

In non-human primates, a single 0.3 mg/kg IV dose of Arcturus' RNAi therapeutic targeting the TTR gene delivered using LUNAR technology led to >75% knockdown of serum TTR protein levels after 10 days,...